Filing Flows › Kura Oncology (KURA) › Q2 2026 › vs Q1 2026
Kura Oncology (KURA) Q2 2026 vs Q1 2026 (quarter over quarter)
Kura Oncology's revenue rose $2.6M (+14%) from $18.3M in Q1 2026 to $20.9M in Q2 2026. The biggest changes: Product +$3.4M (+58%); License and Collaboration Revenue −$747K (-6%).
Kura Oncology, Q2 2026: revenue $20.9M (+36% year over year), operating margin -349.8%, net loss $68.3M, operating cash flow −$62.5M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| License and Collaboration Revenue | $11.8M | $12.5M | −$747K | -6% |
| Product | $9.1M | $5.8M | $3.4M | +58% |
| Revenue | $20.9M | $18.3M | $2.6M | +14% |
| Other income, net | $4.7M | $5.5M | −$802K | -15% |
| Net loss | $68.3M | $73.3M | −$5.0M | -7% |
| Costs & expenses | $93.9M | $97.1M | −$3.2M | -3% |
| Operating costs | $93.9M | $97.1M | −$3.2M | -3% |
| Income tax | $5K | $8K | −$3K | -38% |
| Cost of revenue | $243K | $262K | −$19K | -7% |
| Research & development | $61.9M | $65.3M | −$3.4M | -5% |
| SG&A | $31.8M | $31.6M | $195K | +0.6% |
| Operating cash sources | $71.1M | $94.6M | −$23.5M | -25% |
| Depreciation | $369K | $355K | $14K | +4% |
| Share-based compensation | $8.2M | $8.4M | −$207K | -2% |
| Cash used in operations | $62.5M | $85.9M | −$23.3M | -27% |
| Net loss absorbed | $68.3M | $73.3M | −$5.0M | -7% |
| Working capital & other | $2.8M | $21.3M | −$18.5M | -87% |
Questions
How much did Kura Oncology's revenue grow quarter over quarter in Q2 2026?
Kura Oncology's revenue rose $2.6M (+14%) from $18.3M in Q1 2026 to $20.9M in Q2 2026.
What drove Kura Oncology's revenue change in Q2 2026?
Product +$3.4M (+58%); License and Collaboration Revenue −$747K (-6%).